World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
58
Citations
12210
World Ranking
3518
National Ranking
22

Michael Feldman publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Michael Feldman sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 288 publications — 61st percentile

61% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Michael Feldman D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Michael Feldman sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 58 D-Index — 30th percentile

30% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Michael Feldman was affiliated with the Weizmann Institute of Science in Israel. Their research spanned multiple domains within medicine and economics, particularly focusing on oncology and health economics.

Their work included multiple studies on cancer screening, diagnostics, and economic evaluations in health care. Fields of study covered by the scientist were primarily Medicine and Economics, Econometrics and Finance. Subfields reflected this interdisciplinary approach with publications in Oncology, Economics and Econometrics, Endocrinology, Diabetes and Metabolism, Genetics, and Cancer Research.

Research topics explored by Michael Feldman encompassed:

  • Colorectal Cancer Screening and Detection
  • Global Cancer Incidence and Screening
  • Health Systems, Economic Evaluations, Quality of Life
  • Economic and Financial Impacts of Cancer
  • Cancer Genomics and Diagnostics
  • Diabetes Treatment and Management
  • Diabetes Management and Research

Frequent co-authors included Ali Tafazzoli (10 publications), Karen Chung (8), A. Mark Fendrick (8), Ameya Chavan (6), and Odette S. Reifsnider (5). The scientist's publications appeared often in journals such as Value in Health (7 publications), Journal of the National Comprehensive Cancer Network (4), Annals of Oncology (2), The American Journal of Managed Care (2), and Cancer Epidemiology Biomarkers & Prevention (2).

Recent papers published by Michael Feldman include:

  • Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK (2021, British Journal of Cancer)
  • Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial (2021, American Journal of Kidney Diseases)
  • Patient Preferences for Multi-Cancer Early Detection (MCED) Screening Tests (2022, Patient)
  • The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA (2022, PharmacoEconomics)
  • Health state utility values by cancer stage: a systematic literature review (2021, The European Journal of Health Economics)

Best Publications

  • Long-term cultures of HTLV-III--infected T cells: a model of cytopathology of T-cell depletion in AIDS.

    D Zagury;J Bernard;R Leonard;R Cheynier

  • Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection

    R. Wallich;N. Bulbuc;G. J. Hämmerling;S. Katzav

  • HTLV-III in cells cultured from semen of two patients with AIDS

    D Zagury;J Bernard;J Leibowitch;B Safai

  • CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma

    Ofer Mandelboim;Gideon Berke;Mati Fridkin;Michael Feldman

  • Interleukin 6 Gene Transfection into Lewis Lung Carcinoma Tumor Cells Suppresses the Malignant Phenotype and Confers Immunotherapeutic Competence against Parental Metastatic Cells

    Angel Porgador;Esther Tzehoval;Anne Katz;Ezra Vadai

  • C-C Chemokines, Pivotal in Protection Against HIV Type 1 Infection

    Daniel Zagury;Abderrahim Lachgar;Vida Chams;Lat S. Fall

  • Interferon α and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS

    Daniel Zagury;Abderrahim Lachgar;Vida Chams;Lat S. Fall

  • Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides

    Ofer Mandelboim;Ezra Vadai;Mati Fridkin;Anne Katz-Hillel

  • Isolation and characterization of individual functionally reactive cytotoxic T lymphocytes: conjugation, killing and recycling at the single cell level

    D. Zagury;Jacky Bernard;Noelle Thierness;M. Feldman

  • Differential expression of H–2 gene products in tumour cells is associated with their metastatogenic properties

    Patrick De Baetselier;Shulamit Katzav;Eliezer Gorelik;Michael Feldman

  • Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells.

    A. Porgador;Rajat Bannerji;Y. Watanabe;M. Feldman

  • THE FORMATION OF HYBRID MULTINUCLEATED MUSCLE FIBERS FROM MYOBLASTS OF DIFFERENT GENETIC ORIGIN.

    David Yaffe;Michael Feldman

  • Enhancing T lymphocytes from tumor‐bearing mice suppress host resistance to a syngeneic tumor

    A. J. Treves;C. Carnaud;N. Trainin;M. Feldman

  • MHC imbalance and metastatic spread in Lewis lung carcinoma clones

    Lea Eisenbach;Shraga Segal;Michael Feldman

  • Antigenic Specificity of Benzo[a]pyrene-Induced Sarcomas

    Amiela Globerson;Michael Feldman

  • The differential expression of H-2K versus H-2D antigens, distinguishing high-metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells.

    Lea Eisenbach;Nurit Hollander;Lea Greenfeld;Hadas Yakor

  • Differences in Cell Surface Antigens of Tumor Metastases and Those of the Local Tumor

    Mina Fogel;Eliezer Gorelik;Shraga Segal;Michael Feldman

  • Differences in Resistance of Metastatic Tumor Cells and Cells From Local Tumor Growth to Cytotoxicity of Natural Killer Cells

    Eliezer Gorelik;Mina Fogel;Michael Feldman;Shraga Segal

  • Anti‐metastatic vaccination of tumor‐bearing mice with il‐2‐gene‐inserted tumor cells

    Angel Porgador;Bernd Gansbacher;Rajat Bannerji;Esther Tzehoval

  • Tuftsin (an Ig-associated tetrapeptide) triggers the immunogenic function of macrophages: implications for activation of programmed cells.

    E Tzehoval;S Segal;Y Stabinsky;M Fridkin

  • The frequency of effector cells in populations containing cytotoxic T lymphocytes

    G. Berke;D. Gabison;M. Feldman

Frequent Co-Authors

Shraga Segal
Shraga Segal Ben-Gurion University of the Negev
Irun R. Cohen
Irun R. Cohen Weizmann Institute of Science
Mati Fridkin
Mati Fridkin Weizmann Institute of Science
Gideon Berke
Gideon Berke Weizmann Institute of Science
Angel Porgador
Angel Porgador Ben-Gurion University of the Negev
David Yaffe
David Yaffe Weizmann Institute of Science
Jean-François Zagury
Jean-François Zagury heSam Université
Michel Revel
Michel Revel Weizmann Institute of Science
Michael Sela
Michael Sela Weizmann Institute of Science
Leo Sachs
Leo Sachs Weizmann Institute of Science

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens opportunities not only within research and healthcare but also through complementary nursing and clinical programs. For those interested in advancing quickly, exploring the easiest absn programs to get into can be a strategic route. These programs offer accelerated pathways for registered nurses to earn bachelor’s degrees and expand their career options.

Entry-level nursing roles related to immunology careers can often begin with practical experience gained through programs identified as which lpn programs are easiest to get into. Licensed Practical Nurse programs provide foundational clinical skills applicable in immunology-focused healthcare settings.

For nurses aiming to specialize further, the easiest online nurse practitioner programs provide flexible, accessible options to gain advanced clinical training, often necessary for immunology-related patient care and treatment roles.

Additionally, mental health considerations are vital in immunology research and treatment. Prospective students should consider pmhnp programs online with best clinical placement, which focus on psychiatric mental health nursing and offer strong clinical practicum experiences to enhance care competencies.

Best Scientists Citing Michael Feldman

Recently Published Articles